Quoc Le-Nguyen
Chief Tech/Sci/R&D Officer presso 89BIO, INC.
Patrimonio netto: 3 M $ in data 31/03/2024
Profilo
Quoc Le-Nguyen is currently the Chief Technical Operations Officer & Head-Quality at 89bio, Inc. He previously worked as the Vice President-Manufacturing Operations at Bayer AG from 2007 to 2013 and as the SVP, Global Head-Technical Operations & Quality at Aduro BioTech, Inc. from 2015 to 2018.
Mr. Le-Nguyen completed his undergraduate degree at the University of California.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
89BIO INC
0.24% | 17/02/2024 | 222 149 ( 0.24% ) | 3 M $ | 31/03/2024 |
Posizioni attive di Quoc Le-Nguyen
| Società | Posizione | Inizio |
|---|---|---|
| 89BIO, INC. | Chief Tech/Sci/R&D Officer | 01/03/2019 |
Precedenti posizioni note di Quoc Le-Nguyen
| Società | Posizione | Fine |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2018 |
| BAYER AG | Corporate Officer/Principal | 01/09/2013 |
Formazione di Quoc Le-Nguyen
| University of California | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BAYER AG | Health Technology |
| 89BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Borsa valori
- Insiders
- Quoc Le-Nguyen
